CN-122003494-A - Strain for inhibiting osteoporosis and application thereof

Abstract

The invention relates to a strain for inhibiting osteoporosis and application thereof, in particular to lactobacillus reuteri (Limosillactobacillus reuteri), weissella antrum (WEISSELLA CIBARIA) or a mixed strain containing lactobacillus reuteri and Weissella antrum, a culture thereof, a pharmaceutical composition containing the strain or the culture thereof for preventing or treating osteoporosis and a health functional food composition for preventing or improving osteoporosis.

Inventors

• WEN JICHENG
• Zheng Qixun

Assignees

• 韩国交通大学校产学协力团
• 顺天乡大学校产学协力团

Dates

Publication Date

20260508

Application Date

20240808

Priority Date

20230809

Claims (6)

1. 1. A strain, wherein the strain is lactobacillus reuteri MGE 3301 (Limosillactobacillus reuteri MGE 3301) strain with accession number KCTC 15398 BP.
2. 2. A strain, wherein the strain is a strain of weissella antrum MGE 3110 (WEISSELLA CIBARIA MGE 3110) deposited under accession number KCTC 15399 BP.
3. 3. A mixed strain, wherein the mixed strain comprises lactobacillus reuteri MGE 3301 (Limosillactobacillus reuteri MGE 3301) strain with accession number KCTC 15398BP and a weissella antrum MGE 3110 (WEISSELLA CIBARIA MGE 3110) strain with accession number KCTC 15399 BP.
4. 4. A culture, wherein the culture is a culture of the mixed strain according to claim 3.
5. 5. A pharmaceutical composition for preventing or treating osteoporosis, wherein the pharmaceutical composition for preventing or treating osteoporosis comprises the mixed strain according to claim 3 or the culture according to claim 4.
6. 6. A health functional food composition for preventing or improving osteoporosis, wherein the health functional food composition for preventing or improving osteoporosis comprises the mixed strain according to claim 3 or the culture according to claim 4.

Description

Strain for inhibiting osteoporosis and application thereof Technical Field The invention relates to a strain for inhibiting osteoporosis and application thereof, in particular to lactobacillus reuteri (Limosillactobacillus reuteri), weissella antrum (WEISSELLA CIBARIA) or a mixed strain containing lactobacillus reuteri and Weissella antrum, a culture thereof, a pharmaceutical composition containing the strain or the culture thereof for preventing or treating osteoporosis and a health functional food composition for preventing or improving osteoporosis. Background The global population aging has led to an increase in the number of osteoporotic patients, which has become a prominent public health problem. Osteoporosis is associated with an imbalance in bone metabolism that is greater in bone resorption than bone formation. Osteoporosis treatment is mainly dependent on calcium and vitamin D supplementation, hormone replacement therapy, drug prescriptions, and the like. Calcium and vitamin D supplementation, selective estrogen receptor modulators, hormone replacement therapies, and the like have proven to be effective in reducing bone loss and complex fracture risk in osteoporotic patients. Non-pharmacological treatments include nutritional dietetic therapy, exercise therapy and surgical treatment of bone fractures, and recent research reports indicate that probiotic strains as beneficial human flora are effective in preventing osteoporosis (Microbiol Spectr. 2017 Aug; 5 (4): 10.1128/Microbiolspec. BAD-0015-2016). At present, no raw material for directly adopting probiotics thalli and obtaining the function authentication for improving osteoporosis exists. "Probiotic bacteria" are living bacteria, which means beneficial bacteria capable of producing beneficial effects after being ingested into the human body, and although the consumption rate for osteoporosis-related products is high in korea, there is currently no approved raw material for improving osteoporosis by using the probiotic bacteria. In the above technical background, the present inventors confirmed that lactobacillus reuteri (Limosillactobacillus reuteri), weissella antrum (WEISSELLA CIBARIA) or a mixed strain comprising lactobacillus reuteri and weissella antrum, or a culture thereof can effectively prevent, treat or ameliorate osteoporosis, and completed the present application. Disclosure of Invention Problems to be solved by the invention The object of the present invention is to recognize the aforementioned problems of the prior art, The object of the present invention is to provide a strain of Lactobacillus or a culture thereof. The object of the present invention is to provide a Weissella strain or a culture thereof. The object of the present invention is to provide a mixed strain comprising a Lactobacillus strain and a Weissella strain or a culture thereof. The invention aims to provide a pharmaceutical or health functional food composition for preventing, treating or improving osteoporosis, comprising the mixed strain or a culture thereof. Means for solving the problems In order to achieve the above object, the present invention provides a lactobacillus reuteri MGE 3301 (Limosillactobacillus reuteri MGE 3301) strain having accession number KCTC 15398BP or a culture thereof. The present invention also provides a strain of Weissella antrum MGE 3110 (WEISSELLA CIBARIA MGE 3110) deposited under accession number KCTC 15399BP or a culture thereof. The present invention also provides a mixed strain comprising lactobacillus reuteri MGE 3301 (Limosillactobacillus reuteri MGE 3301) strain with accession number KCTC 15398BP and westernia antrum MGE 3110 (WEISSELLA CIBARIA MGE 3110) strain with accession number KCTC 15399 BP. The invention also provides a culture of the mixed strain. The present invention also provides a pharmaceutical composition for preventing or treating osteoporosis comprising the mixed strain or a culture thereof. The invention also provides a health functional food composition for preventing or improving osteoporosis, comprising the mixed strain or a culture thereof. Effects of the invention It has been confirmed by the present invention that probiotics comprising lactobacillus reuteri Limosillactobacillus reuteri MGE strain 3301 isolated from healthy infant feces, weissella antrum WEISSELLA CIBARIA MGE strain 3110 isolated from kimchi or a mixed strain of both strains have excellent effects in improving osteoporosis. Drawings FIG. 1 shows the changes in bone trabecular volume (BV/TV,%) and bone density (BMD, g/cm 2) in an animal model of menopause, caused by orally administered lactic acid bacteria strains. Sram, control group, OVX, ovariectomized mice, LR, oral administration of Lactobacillus reuteri MGE 3301 (Limosillactobacillus reuteri MGE 3301) (. About.10 9 cells/0.1 g/day), WC, oral administration of Weissella food MGE 3110 (WEISSELLA CIBARIA MGE 3110) (. About.10 9 cells/0.1 g/day), oral administration of M, oral admini